Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...

Key Points Interested in Candel Therapeutics, Inc.? Here are five stocks we like better. Candel Therapeutics said it remains on track to file a BLA by year-end for aglatimagene in localized prostate ...

Men given two larger doses of radiation had about the same side effects as others treated with the standard five-dose course, ...

Partnering with University of Michigan Health represents an important step in bringing Unfold AI to leading cancer centers ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

A new podcast fronted by writer, comedian and broadcaster Jon Holmes is aiming to help men better understand their prostate cancer treatment options ...

Prostate cancer is the most commonly diagnosed cancer in the UK, with more than 63,000 new cases each year. Yet for many men, understanding their treatment options remains far from straightforward ...

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.

Aglatimagene plus prodrug and standard of care EBRT significantly improved prostate cancer-specific DFS by 39% versus placebo in men with localized prostate cancer, especially those with ...

The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...